Cantor Fitzgerald Starts Omnicell (OMCL) at Overweight

Cantor Fitzgerald initiates coverage on Omnicell (NASDAQ: OMCL) with a Overweight rating and a price target of $40.00.

Analyst Steven Halper commented, "We initiate coverage of Omnicell with an Overweight rating and $40 PT in 12 months. The company maintains the No. 2 market share position within the automated medication dispensing cabinet market. Over the years, OMCL has broadened its product set to improve hospital pharmacy efficiencies beyond dispensing. Based on its product differentiation and lower cost of ownership, we expect OMCL to continue to gain market share from industry leader, Pyxis, a subsidiary of Becton, Dickinson. OMCL has about 40% share and is likely to gain 1-2% each year, equating to about 100-150 hospitals annually."

For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.

Shares of Omnicell closed at $33.30 yesterday.

You May Also Be Interested In

• Raymond James Starts Civeo (CVEO) at Strong Buy
• Caterpillar (CAT) PT Raised to $1,118 at Oppenheimer
• Wolfe Research Starts SK Hynix (SKHY) at Outperform